Embracing the Evolving Era of Pharmacotherapy in Obesity Management: Pharmacist Viewpoints on Unbiased, Data-Driven Treatment
Tracking # 20-1315056
Free
Course overview
To equip ambulatory care clinical pharmacists with the knowledge, confidence, and tools they need to provide equitable, unbiased care for patients with overweight or obesity and interpolate novel anti-obesity medications into clinical practice on a patient-centric and evidence-driven basis, with emphasis on the evolving role of incretin analogues in the rapidly shifting treatment calculus.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
Jennifer N. Clements, PharmD, BCPS, BCACP, BC-ADM, CDCES, FCCP, FADCES discloses the following: Speaker’s bureau - Eli Lilly and Novo Nordisk.
The clinical reviewer, Darrell Hulisz, RPh, PharmD has no relevant affiliations, no financial relationships or relationships to products or devices with a commercial interest related to the content of this activity to disclose.
Susanne Kwas, MSHF, BSN, RN, Robin Carrino and Alexia Hynes, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.